EAST RUTHERFORD, N.J.
Jan. 18, 2011
/PRNewswire/ -- Cambrex Corporation (NYSE: CBM) announced today that the Danish Medicines Agency (DKMA) has issued a Certificate of Good Manufacturing Practice (GMP) compliance for its manufacturing site in
, following an audit conducted in
. The DKMA Certificate is accepted by all EU Health Authorities and by authorities of several other countries that recognize EU Certification.
, President of Cambrex Zenara, commented, "We are very pleased with the results of the DKMA inspection. This commercially important and significant milestone for Cambrex confirms our commitment to quality in every aspect of operations management and reflects our efforts to sustain and continuously improve quality platforms."
The DKMA certification allows Cambrex to expedite the European rollout of Nicotine Replacement Therapy (NRT) products (chewing gums, lozenges and mini-lozenges), in addition to offering finished dosage forms of other pharmaceutical products to our European customers through an integrated value chain.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit
SOURCE Cambrex Corporation